Dr. Sina Habibi reports

COGNETIVITY NEUROSCIENCES PARTNERS WITH NO FEAR COUNSELLING TO PIONEER BRAIN HEALTH ASSESSMENT THROUGH GROUNDBREAKING AI TECHNOLOGY

Cognetivity Neurosciences Ltd. has formed a partnership with No Fear Counselling, the leading and rapidly growing Vancouver-based counselling practice with over 150 therapists and a network of 60 locations. This groundbreaking partnership, utilizing Cognetivity's artificial intelligence-powered CognICA technology, promises to usher in a new era of mental well-being by providing cutting-edge tools to assess and enhance cognitive health.

In today's ever-evolving landscape of mental health, the need for effective interventions and continuous monitoring of cognitive well-being has never been more crucial, but until now the ability to precisely and frequently measure cognitive function has not been available outside of expensive clinics. No Fear Counselling recognizes this imperative and is committed to offering its clients the most advanced solutions available. With the Canadian mental health market estimated at $1.68-billion (U.S.) in 2023, and the overall U.S. behavioural health market size of $87.3-billion in 2022, rising to $136.6-billion by 2032, the delivery of these represents a high-growth opportunity for both No Fear and Cognetivity.

Cognetivity's revolutionary AI technology offers a quick and simple-to-use, yet powerful, means to measure and understand brain health, through its ability to measure small changes in brain function, allowing detection of brain health issues at the earliest stage and measuring the impact of interventions such as therapy and counselling. In the treatment of mental health issues, this capability enables a more profound connection and feedback on treatment effectiveness between patients and therapists, enabling personalized and effective care like never before. By partnering with Cognetivity, No Fear Counselling is demonstrating its unwavering dedication to providing clients with comprehensive and cutting-edge mental health care.

"No Fear Counselling is thrilled to join forces with Cognetivity to elevate our commitment to our clients' mental well-being," said Harry Parmar, managing partner at No Fear Counselling. "As effective interventions emerge for cognitive decline, there has never been a more important time to consistently check in with your brain health. With the right measurement tool, our brains can get the attention they deserve -- and that tool is Cognetivity."

"No Fear Counselling's deserved reputation as a leader in the counselling industry aligns perfectly with our mission to empower individuals with the ability to monitor and improve their cognitive health," said Sina Habibi, chief executive officer at Cognetivity stated. "By adding the unique capabilities of our CognICA technology to detect brain health issues, give feedback and measure the impact of interventions, whether clinical, through therapy or lifestyle improvement, No Fear stands at the forefront of the next generation of effective, personalized care. We're very excited to embark on this journey together, redefining the standards of mental health care."

The collaboration between No Fear Counselling and Cognetivity is a testament to their shared vision of a future where mental health is enhanced through accessible, innovative and personalized solutions. It marks a significant milestone in the evolution of mental health care, setting a new standard for the industry and opening a vast market in North America and beyond. This approach aligns perfectly with Cognetivity Neurosciences' mission to utilize its AI platform technology to transform the landscape of brain health globally, enhance the quality of care provided to patients, and to reduce the burden and cost to providers and payers, delivering the company's vision of a brighter mind for a fuller life.

The company has also issued to certain employees 968,000 common shares of the company at 15 cents per share as consideration for their services and loyalty for the last year during the challenging financial markets.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has developed a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's CognICA uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. CognICA is currently available for clinical use in the United States, the United Kingdom, Europe, Canada and the Middle East, with regulatory approval in other regions expected later in 2023.

We seek Safe Harbor.